SCHEMBL195956

SCHEMBL195956

CC(C(=O)O)c1ccc(Cl)cc1C(F)(F)F

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 7/20 0.47
AKR1C2 P52895 7/20 0.47
POLQ O75417 1/20 0.46
RAB9A P51151 3/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C19 P33261 1/20 0.43
HTT P42858 2/20 0.41
NPC1 O15118 1/20 0.41
ALDH1A1 P00352 1/20 0.41
PAX8 Q06710 1/20 0.41
MAPT P10636 2/20 0.40
TP53 P04637 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
PTGS2 P35354 2/20 0.40
KDM4E B2RXH2 1/20 0.40
MEN1 O00255 1/20 0.40
ABCC4 O15439 1/20 0.40
C5 P01031 1/20 0.40
PTGS1 P23219 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29009925 0.87 AKR1C3 (0.47) AKR1C3AKR1C2POLQRAB9ACYP1A2
SCHEMBL30428378 0.82 CES2 (0.50) AKR1C3AKR1C2POLQALDH1A1MAPT
SCHEMBL19183089 0.82 AKR1C3 (0.46) AKR1C3AKR1C2PTGS2PTGS1
SCHEMBL14661510 0.82 RAB9A (0.44) POLQRAB9ACYP1A2CYP2D6CYP2C19
SCHEMBL29009908 0.81 AKR1C3 (0.52) AKR1C3AKR1C2PTGS2MEN1PTGS1
SCHEMBL29010054 0.81 RAB9A (0.43) POLQRAB9ACYP1A2CYP2D6CYP2C19
SCHEMBL10039365 0.79 NOTUM (0.43) POLQRAB9ACYP1A2CYP2D6CYP2C19
SCHEMBL9900630 0.78 PTGS2 (0.52) MAPTPTGS2MEN1ABCC4C5
SCHEMBL838637 0.78 LMNA (0.55) HTTMAPTTP53SMN1; SMN2PTGS2
SCHEMBL15641246 0.78 LMNA (0.55) HTTMAPTTP53SMN1; SMN2PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120053171-A1 Nitrogen-Containing Fused Heterocyclic Compounds and Their use as Beta Amyloid Production Inhibitors EISAI R&D MANAGEMENT CO., LTD., (JP) 2012-03-01 US disclosed
EP-2401276-A1 NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS BETA AMYLOID PRODUCTION INHIBITORS Eisai R&D Management Co., Ltd. (JP) 2012-01-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053171-A1 Nitrogen-Containing Fused Heterocyclic Compounds and Their use as Beta Amyloid Production Inhibitors BACE1, APP, PSEN1 AKR1C3 841/4885AKR1C2 1587/4885POLQ 2406/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.